McCullough PA, et al. - Researchers assessed the utility of oral ferric citrate vs placebo in patients with iron-deficiency anemia (IDA) and chronic kidney disease (CKD) not on dialysis with or without heart failure (HF), focusing on changes in hemoglobin, transferrin saturation, ferritin, and serum phosphate from baseline to week 12 of intervention and the incidence of adverse events potentially related to HF. Between patients with and without HF, no significant difference was seen in the proportion of patients with hemoglobin response to ferric citrate treatment. Patients with HF vs those without HF more frequently suffered adverse events potentially related to HF. Overall, findings suggested a potential role for ferric citrate in the treatment of IDA in patients with CKD not on dialysis and concomitant HF.